Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHIs

Anemia in CKD is associated with increased risk of CKD progression, poor CV outcomes, decreased health-related quality of life, and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Share

Provided by

ProCE Banner
ProCE Banner

Jointly provided by USFH and Rockpointe.

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline